{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:44:51Z","timestamp":1792788291881,"version":"4.5.0"},"reference-count":110,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T00:00:00Z","timestamp":1791590400000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["L248022"],"award-info":[{"award-number":["L248022"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National High Level Hospital Clinical Research Funding","award":["2025-PUMCH-C-015, 2022-PUMCH-B-128, 2025-PUMCH-D-001"],"award-info":[{"award-number":["2025-PUMCH-C-015, 2022-PUMCH-B-128, 2025-PUMCH-D-001"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2022-I2M-C&T-A-003, 2021-I2M-1-061, 2021-I2M-1-003"],"award-info":[{"award-number":["2022-I2M-C&T-A-003, 2021-I2M-1-061, 2021-I2M-1-003"]}]},{"name":"Hangzhou East Clinical Oncology Research Center Programme","award":["ECCO-KY-25004"],"award-info":[{"award-number":["ECCO-KY-25004"]}]},{"name":"Beijing Bethune Charitable Foundation","award":["GDZL024"],"award-info":[{"award-number":["GDZL024"]}],"id":[{"id":"https:\/\/ror.org\/0430c7a41","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08750-6","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T16:53:43Z","timestamp":1785776023000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Decoding the cholangiocarcinoma tumor microenvironment: from single-cell and spatial atlases to translational therapeutic targeting"],"prefix":"10.1186","volume":"24","author":[{"given":"Longhao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingnan","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3444-8044","authenticated-orcid":false,"given":"Haitao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"8750_CR1","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41572-021-00300-2","volume":"7","author":"PJ Brindley","year":"2021","unstructured":"Brindley PJ, Bachini M, Ilyas SI, Khan SA, Loukas A, Sirica AE, Teh BT, Wongkham S, Gores GJ. Cholangiocarcinoma. Nat reviews Disease primers. 2021;7:65.","journal-title":"Nat reviews Disease primers"},{"key":"8750_CR2","doi-asserted-by":"crossref","first-page":"403","DOI":"10.6004\/jnccn.2025.0042","volume":"23","author":"AB Benson","year":"2025","unstructured":"Benson AB, D\u2019angelica MI, Abrams T, Ahmed A, Akce M, Anaya DA, Anders R, Are C, Aye L, Bachini M. Biliary tract cancers, Version 2.2025, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2025;23:403\u201318.","journal-title":"J Natl Compr Canc Netw"},{"key":"8750_CR3","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17","author":"JM Banales","year":"2020","unstructured":"Banales JM, Marin JJ, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, Cardinale V, Carpino G, Andersen JB, Braconi C. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat reviews Gastroenterol Hepatol. 2020;17:557\u201388.","journal-title":"Nat reviews Gastroenterol Hepatol"},{"key":"8750_CR4","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jhep.2023.03.010","volume":"79","author":"Liver","year":"2023","unstructured":"Liver, EAftSoT. EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma. J Hepatol. 2023;79:181\u2013208.","journal-title":"J Hepatol"},{"key":"8750_CR5","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jhep.2025.03.007","volume":"83","author":"M Marzioni","year":"2025","unstructured":"Marzioni M, Maroni L, Aabakken L, Carpino G, Koerkamp BG, Heimbach J, Khan S, Lamarca A, Saborowski A, Vilgrain V. EASL Clinical Practice Guidelines on the management of extrahepatic cholangiocarcinoma. J Hepatol. 2025;83:211\u201338.","journal-title":"J Hepatol"},{"key":"8750_CR6","doi-asserted-by":"publisher","first-page":"3293","DOI":"10.1007\/s12094-025-03916-y","volume":"27","author":"T Macarulla","year":"2025","unstructured":"Macarulla T, Adeva J, Cano Osuna MT, Ruiz Casado A, Jim\u00e9nez Gordo AM, Lamarca A, L\u00f3pez Mu\u00f1oz AM, Pazo Cid RA, Saur\u00ed T, Gallego Plazas J. SEOM-GEMCAD-TTD clinical guidelines for biliary tract cancer (2025). Clin Transl Oncol. 2025;27:3293\u2013306.","journal-title":"Clin Transl Oncol"},{"key":"8750_CR7","doi-asserted-by":"crossref","first-page":"e2400206","DOI":"10.1200\/PO.24.00206","volume":"8","author":"WA Preston","year":"2024","unstructured":"Preston WA, Drill E, Boerner T, Gelfer R, Harding JJ, O\u2019Reilly EM, Cercek A, Abou-Alfa G, Park W, Balachandran VP. Extrahepatic cholangiocarcinoma: Genomic variables associated with anatomic location and outcome. JCO precision Oncol. 2024;8:e2400206.","journal-title":"JCO precision Oncol"},{"key":"8750_CR8","doi-asserted-by":"crossref","unstructured":"Shibata T, Nakamura H, Hosoda F, Elzawahry A, Shirota T, Totoki Y, Kato M, Kosuge T, Hiraoka N, Shimada K. Genomic spectra of biliary tract cancer. Nat Genet. 2015:47.","DOI":"10.1038\/ng.3375"},{"key":"8750_CR9","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","volume":"7","author":"A Jusakul","year":"2017","unstructured":"Jusakul A, Cutcutache I, Yong CH, Lim JQ, Huang MN, Padmanabhan N, Nellore V, Kongpetch S, Ng AWT, Ng LM. Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma. Cancer Discov. 2017;7:1116\u201335.","journal-title":"Cancer Discov"},{"key":"8750_CR10","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1016\/j.celrep.2017.02.033","volume":"18","author":"F Farshidfar","year":"2017","unstructured":"Farshidfar F, Zheng S, Gingras M-C, Newton Y, Shih J, Robertson AG, Hinoue T, Hoadley KA, Gibb EA, Roszik J. Integrative genomic analysis of cholangiocarcinoma identifies distinct IDH-mutant molecular profiles. Cell Rep. 2017;18:2780\u201394.","journal-title":"Cell Rep"},{"key":"8750_CR11","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jhep.2018.01.009","volume":"68","author":"CP Wardell","year":"2018","unstructured":"Wardell CP, Fujita M, Yamada T, Simbolo M, Fassan M, Karlic R, Polak P, Kim J, Hatanaka Y, Maejima K. Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations. J Hepatol. 2018;68:959\u201369.","journal-title":"J Hepatol"},{"key":"8750_CR12","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2020.03.008","volume":"73","author":"R Montal","year":"2020","unstructured":"Montal R, Sia D, Montironi C, Leow WQ, Esteban-Fabro R, Pinyol R, Torres-Martin M, Bassaganyas L, Moeini A, Peix J. Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma. J Hepatol. 2020;73:315\u201327.","journal-title":"J Hepatol"},{"key":"8750_CR13","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1002\/cncr.30254","volume":"122","author":"M Javle","year":"2016","unstructured":"Javle M, Bekaii-Saab T, Jain A, Wang Y, Kelley RK, Wang K, Kang HC, Catenacci D, Ali S, Krishnan S. Biliary cancer: utility of next\u2010generation sequencing for clinical management. Cancer. 2016;122:3838\u201347.","journal-title":"Cancer"},{"key":"8750_CR14","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","volume":"388","author":"L Goyal","year":"2023","unstructured":"Goyal L, Meric-Bernstam F, Hollebecque A, Valle JW, Morizane C, Karasic TB, Abrams TA, Furuse J, Kelley RK, Cassier PA. Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma. N Engl J Med. 2023;388:228\u201339.","journal-title":"N Engl J Med"},{"key":"8750_CR15","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jamaoncol.2021.3836","volume":"7","author":"AX Zhu","year":"2021","unstructured":"Zhu AX, Macarulla T, Javle MM, Kelley RK, Lubner SJ, Adeva J, Cleary JM, Catenacci DV, Borad MJ, Bridgewater JA. Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial. JAMA Oncol. 2021;7:1669\u201377.","journal-title":"JAMA Oncol"},{"key":"8750_CR16","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S1470-2045(23)00242-5","volume":"24","author":"JJ Harding","year":"2023","unstructured":"Harding JJ, Fan J, Oh D-Y, Choi HJ, Kim JW, Chang H-M, Bao L, Sun H-C, Macarulla T, Xie F. Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study. Lancet Oncol. 2023;24:772\u201382.","journal-title":"Lancet Oncol"},{"key":"8750_CR17","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.2217\/fon-2022-0214","volume":"18","author":"A Ohba","year":"2022","unstructured":"Ohba A, Morizane C, Ueno M, Kobayashi S, Kawamoto Y, Komatsu Y, Ikeda M, Sasaki M, Okano N, Furuse J. Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial. Future Oncol. 2022;18:2351\u201360.","journal-title":"Future Oncol"},{"key":"8750_CR18","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","volume":"21","author":"GK Abou-Alfa","year":"2020","unstructured":"Abou-Alfa GK, Sahai V, Hollebecque A, Vaccaro G, Melisi D, Al-Rajabi R, Paulson AS, Borad MJ, Gallinson D, Murphy AG. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21:671\u201384.","journal-title":"Lancet Oncol"},{"key":"8750_CR19","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.jhep.2023.10.041","volume":"80","author":"TP DiPeri","year":"2024","unstructured":"DiPeri TP, Zhao M, Evans KW, Varadarajan K, Moss T, Scott S, Kahle MP, Byrnes CC, Chen H, Lee SS. Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma. J Hepatol. 2024;80:322\u201334.","journal-title":"J Hepatol"},{"key":"8750_CR20","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1038\/s41591-023-02321-8","volume":"29","author":"V Subbiah","year":"2023","unstructured":"Subbiah V, Kreitman RJ, Wainberg ZA, Gazzah A, Lassen U, Stein A, Wen PY, Dietrich S, de Jonge MJ, Blay J-Y. Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial. Nat Med. 2023;29:1103\u201312.","journal-title":"Nat Med"},{"key":"8750_CR21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","volume":"38","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Le DT, Ascierto PA, Di Giacomo AM, De Jesus-Acosta A, Delord J-P, Geva R, Gottfried M, Penel N, Hansen AR. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability\/mismatch repair\u2013deficient cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38:1\u201310.","journal-title":"J Clin Oncol"},{"key":"8750_CR22","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1200\/PO.20.00178","volume":"5","author":"AM Varghese","year":"2021","unstructured":"Varghese AM, Patel J, Janjigian YY, Meng F, Selcuklu SD, Iyer G, Houck-Loomis B, Harding JJ, O\u2019Reilly EM, Abou-Alfa GK. Noninvasive detection of polyclonal acquired resistance to FGFR inhibition in patients with cholangiocarcinoma harboring FGFR2 alterations. JCO Precision Oncol. 2021;5:44\u201350.","journal-title":"JCO Precision Oncol"},{"key":"8750_CR23","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40164-023-00470-7","volume":"13","author":"C Astier","year":"2024","unstructured":"Astier C, Ngo C, Colmet-Daage L, Marty V, Bawa O, Nicotra C, Ngo-Camus M, Italiano A, Massard C, Scoazec J-Y. Molecular profiling of biliary tract cancers reveals distinct genomic landscapes between circulating and tissue tumor DNA. Experimental Hematol Oncol. 2024;13:2.","journal-title":"Experimental Hematol Oncol"},{"key":"8750_CR24","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13045-022-01253-z","volume":"15","author":"T Xia","year":"2022","unstructured":"Xia T, Li K, Niu N, Shao Y, Ding D, Thomas DL, Jing H, Fujiwara K, Hu H, Osipov A. Immune cell atlas of cholangiocarcinomas reveals distinct tumor microenvironments and associated prognoses. J Hematol Oncol. 2022;15:37.","journal-title":"J Hematol Oncol"},{"key":"8750_CR25","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/hep.31410","volume":"73","author":"L Fabris","year":"2021","unstructured":"Fabris L, Sato K, Alpini G, Strazzabosco M. The tumor microenvironment in cholangiocarcinoma progression. Hepatology. 2021;73:75\u201385.","journal-title":"Hepatology"},{"key":"8750_CR26","doi-asserted-by":"crossref","first-page":"1037945","DOI":"10.3389\/fimmu.2023.1037945","volume":"14","author":"X Yu","year":"2023","unstructured":"Yu X, Zhu L, Wang T, Chen J. Immune microenvironment of cholangiocarcinoma: Biological concepts and treatment strategies. Front Immunol. 2023;14:1037945.","journal-title":"Front Immunol"},{"key":"8750_CR27","doi-asserted-by":"crossref","first-page":"5380","DOI":"10.1172\/JCI137110","volume":"130","author":"E Loeuillard","year":"2020","unstructured":"Loeuillard E, Yang J, Buckarma E, Wang J, Liu Y, Conboy C, Pavelko KD, Li Y, O\u2019Brien D, Wang C. Targeting tumor-associated macrophages and granulocytic myeloid-derived suppressor cells augments PD-1 blockade in cholangiocarcinoma. J Clin Investig. 2020;130:5380\u201396.","journal-title":"J Clin Investig"},{"key":"8750_CR28","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang Y, Kadel Iii EE, Koeppen H, Astarita JL, Cubas R. TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554:544\u20138.","journal-title":"Nature"},{"key":"8750_CR29","doi-asserted-by":"crossref","unstructured":"Feig C, Jones JO, Kraman M, Wells RJ, Deonarine A, Chan DS, Connell CM, Roberts EW, Zhao Q, Caballero OL. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti\u2013PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci USA. 2013;110:20212\u201320217.","DOI":"10.1073\/pnas.1320318110"},{"key":"8750_CR30","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","volume":"15","author":"D Fukumura","year":"2018","unstructured":"Fukumura D, Kloepper J, Amoozgar Z, Duda DG, Jain RK. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat reviews Clin Oncol. 2018;15:325\u201340.","journal-title":"Nat reviews Clin Oncol"},{"key":"8750_CR31","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1007\/s00262-017-2003-1","volume":"66","author":"H Jiang","year":"2017","unstructured":"Jiang H, Hegde S, DeNardo DG. Tumor-associated fibrosis as a regulator of tumor immunity and response to immunotherapy. Cancer Immunol Immunother. 2017;66:1037\u201348.","journal-title":"Cancer Immunol Immunother"},{"key":"8750_CR32","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.tcb.2014.11.006","volume":"25","author":"F Klemm","year":"2015","unstructured":"Klemm F, Joyce JA. Microenvironmental regulation of therapeutic response in cancer. Trends Cell Biol. 2015;25:198\u2013213.","journal-title":"Trends Cell Biol"},{"key":"8750_CR33","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41577-019-0127-6","volume":"19","author":"DG DeNardo","year":"2019","unstructured":"DeNardo DG, Ruffell B. Macrophages as regulators of tumour immunity and immunotherapy. Nat Rev Immunol. 2019;19:369\u201382.","journal-title":"Nat Rev Immunol"},{"key":"8750_CR34","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/nri.2017.11","volume":"17","author":"O Krenkel","year":"2017","unstructured":"Krenkel O, Tacke F. Liver macrophages in tissue homeostasis and disease. Nat Rev Immunol. 2017;17:306\u201321.","journal-title":"Nat Rev Immunol"},{"key":"8750_CR35","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s43556-025-00330-2","volume":"6","author":"N Tang","year":"2025","unstructured":"Tang N, Li J, Gu A, Li M, Liu Y. Single-cell multi-omics in biliary tract cancers: decoding heterogeneity, microenvironment, and treatment strategies. Mol Biomed. 2025;6:82.","journal-title":"Mol Biomed"},{"key":"8750_CR36","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.jhep.2020.05.039","volume":"73","author":"M Zhang","year":"2020","unstructured":"Zhang M, Yang H, Wan L, Wang Z, Wang H, Ge C, Liu Y, Hao Y, Zhang D, Shi G. Single-cell transcriptomic architecture and intercellular crosstalk of human intrahepatic cholangiocarcinoma. J Hepatol. 2020;73:1118\u201330.","journal-title":"J Hepatol"},{"key":"8750_CR37","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.jhep.2022.05.043","volume":"77","author":"G Alvisi","year":"2022","unstructured":"Alvisi G, Termanini A, Soldani C, Portale F, Carriero R, Pilipow K, Costa G, Polidoro M, Franceschini B, Malenica I. Multimodal single-cell profiling of intrahepatic cholangiocarcinoma defines hyperactivated Tregs as a potential therapeutic target. J Hepatol. 2022;77:1359\u201372.","journal-title":"J Hepatol"},{"key":"8750_CR38","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1038\/s41467-022-29164-0","volume":"13","author":"G Song","year":"2022","unstructured":"Song G, Shi Y, Meng L, Ma J, Huang S, Zhang J, Wu Y, Li J, Lin Y, Yang S. Single-cell transcriptomic analysis suggests two molecularly distinct subtypes of intrahepatic cholangiocarcinoma. Nat Commun. 2022;13:1642.","journal-title":"Nat Commun"},{"key":"8750_CR39","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jhep.2021.06.028","volume":"75","author":"L Ma","year":"2021","unstructured":"Ma L, Wang L, Khatib SA, Chang C-W, Heinrich S, Dominguez DA, Forgues M, Candia J, Hernandez MO, Kelly M. Single-cell atlas of tumor cell evolution in response to therapy in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. J Hepatol. 2021;75:1397\u2013408.","journal-title":"J Hepatol"},{"key":"8750_CR40","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1158\/0008-5472.CAN-24-1173","volume":"85","author":"J Nie","year":"2025","unstructured":"Nie J, Zhang S, Guo Y, Liu C, Shi J, Wu H, Na R, Liang Y, Yu S, Quan F. Mapping of the T-cell landscape of biliary tract cancer unravels anatomic subtype-specific heterogeneity. Cancer Res. 2025;85:704\u201322.","journal-title":"Cancer Res"},{"key":"8750_CR41","doi-asserted-by":"crossref","first-page":"101275","DOI":"10.1016\/j.jhepr.2024.101275","volume":"7","author":"Z Li","year":"2025","unstructured":"Li Z, Ma L, Chen M, Chen X, Sha M, Hang H. Single-cell analyses reveal metastasis mechanism and microenvironment remodeling of lymph node in intrahepatic cholangiocarcinoma. JHEP Rep. 2025;7:101275.","journal-title":"JHEP Rep"},{"key":"8750_CR42","doi-asserted-by":"crossref","first-page":"2412740","DOI":"10.1002\/advs.202412740","volume":"12","author":"L Zuyin","year":"2025","unstructured":"Zuyin L, Zhao L, Qian C, Changkun Z, Delin M, Jialing H, Zhuomiaoyu C, Yuzi L, Jiaxi Z, Jie G. Single-Cell and Spatial Transcriptomics Delineate the Microstructure and Immune Landscape of Intrahepatic Cholangiocarcinoma in the Leading\u2010Edge Area. Adv Sci. 2025;12:2412740.","journal-title":"Adv Sci"},{"key":"8750_CR43","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/HEP.0000000000001283","volume":"83","author":"L Hong","year":"2026","unstructured":"Hong L, Mei J, Sun X, Wu Y, Dong Z, Jin Y, Gao L, Cheng J, Tian W, Liu C. Spatial single-cell proteomics landscape decodes the tumor microenvironmental ecosystem of intrahepatic cholangiocarcinoma. Hepatology. 2026;83:57\u201374.","journal-title":"Hepatology"},{"key":"8750_CR44","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/s41587-021-01139-4","volume":"40","author":"V Kleshchevnikov","year":"2022","unstructured":"Kleshchevnikov V, Shmatko A, Dann E, Aivazidis A, King HW, Li T, Elmentaite R, Lomakin A, Kedlian V, Gayoso A. Cell2location maps fine-grained cell types in spatial transcriptomics. Nat Biotechnol. 2022;40:661\u201371.","journal-title":"Nat Biotechnol"},{"key":"8750_CR45","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/s41592-021-01358-2","volume":"19","author":"G Palla","year":"2022","unstructured":"Palla G, Spitzer H, Klein M, Fischer D, Schaar AC, Kuemmerle LB, Rybakov S, Ibarra IL, Holmberg O. Virshup I: Squidpy: a scalable framework for spatial omics analysis. Nat Methods. 2022;19:171\u20138.","journal-title":"Nat Methods"},{"key":"8750_CR46","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1038\/s41596-024-01137-1","volume":"20","author":"K Troul\u00e9","year":"2025","unstructured":"Troul\u00e9 K, Petryszak R, Cakir B, Cranley J, Harasty A, Prete M, Tuong ZK, Teichmann SA, Garcia-Alonso L, Vento-Tormo R. CellPhoneDB v5: inferring cell\u2013cell communication from single-cell multiomics data. Nat Protoc. 2025;20:3412\u201340.","journal-title":"Nat Protoc"},{"key":"8750_CR47","doi-asserted-by":"crossref","unstructured":"Li F, Li Y, Wang L, Xu L, Xue H, Wei W, Xia Y, Wang L, Shen F, Wang K. Tumor microenvironment heterogeneity and progression mechanisms in intrahepatic cholangiocarcinoma: a study based on single-cell and spatial transcriptomic sequencing. Hepatology. 2025:101097.","DOI":"10.1097\/HEP.0000000000001423"},{"key":"8750_CR48","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/s13045-025-01716-z","volume":"18","author":"C Liu","year":"2025","unstructured":"Liu C, Wang X, Liu E, Zong Y, Yu W, Jiang Y, Chen J, Gu M, Meng Z, Li J. Deciphering cholangiocarcinoma heterogeneity and specific progenitor cell niche of extrahepatic cholangiocarcinoma at single-cell resolution. J Hematol Oncol. 2025;18:66.","journal-title":"J Hematol Oncol"},{"key":"8750_CR49","doi-asserted-by":"crossref","unstructured":"Zhang Z, Dou H, Zhao S, Wang J, Chen M, Xie X, Tian X, Zhao D. Single-cell multi-omics analysis reveals drivers of intrahepatic cholangiocarcinoma metastasis. BMC Cancer. 2025.","DOI":"10.1186\/s12885-025-15253-y"},{"key":"8750_CR50","doi-asserted-by":"crossref","unstructured":"Xun Z, Wang H, Xuan Z, Xiong K, Zhang N, Long J, Sun H, Li Y, Zhu C, Piao M. Spatiotemporal landscape of intrahepatic cholangiocarcinoma liver metastasis at the single-cell level. Hepatology. 2025:101097.","DOI":"10.1097\/HEP.0000000000001641"},{"key":"8750_CR51","first-page":"167276","volume":"1870","author":"Y Liang","year":"2024","unstructured":"Liang Y, Bu Q, You W, Zhang R, Xu Z, Gan X, Zhou J, Qiao L, Huang T, Lu L. Single-cell analysis reveals hypoxia-induced immunosuppressive microenvironment in intrahepatic cholangiocarcinoma. Biochim et Biophys Acta (BBA)-Molecular Basis Disease. 2024;1870:167276.","journal-title":"Biochim et Biophys Acta (BBA)-Molecular Basis Disease"},{"key":"8750_CR52","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","volume":"20","author":"E Sahai","year":"2020","unstructured":"Sahai E, Astsaturov I, Cukierman E, DeNardo DG, Egeblad M, Evans RM, Fearon D, Greten FR, Hingorani SR, Hunter T. A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer. 2020;20:174\u201386.","journal-title":"Nat Rev Cancer"},{"key":"8750_CR53","doi-asserted-by":"crossref","unstructured":"Milardi G, Franceschini B, Camisaschi C, Puccio S, Costa G, Soldani C, Uva P, Cangelosi D, Carriero R, Lambroia L. Immunosuppressive contribution of tumour-infiltrating B cells in human intrahepatic cholangiocarcinoma and their role in chemoimmunotherapy outcome. Gut. 2025.","DOI":"10.1136\/gutjnl-2025-334861"},{"key":"8750_CR54","doi-asserted-by":"crossref","first-page":"mjae023","DOI":"10.1093\/jmcb\/mjae023","volume":"16","author":"Q Cao","year":"2024","unstructured":"Cao Q, Yang J, Jiang L, Yang Z, Fan Z, Chen S, Zhu S, Yin L, Wang H, Wen W. Single-cell analysis defines LGALS1\u2009+\u2009fibroblasts that promote proliferation and migration of intrahepatic cholangiocarcinoma. J Mol Cell Biol. 2024;16:mjae023.","journal-title":"J Mol Cell Biol"},{"key":"8750_CR55","doi-asserted-by":"crossref","first-page":"e010173","DOI":"10.1136\/jitc-2024-010173","volume":"13","author":"S-Y Chung","year":"2025","unstructured":"Chung S-Y, Yeh Y-C, Huang C-J, Chiang N-J, Hsu DS-S, Chan M-H, Lu M-L, Hsu T-S, Hung Y-P, Yeh C-N. Comparative impact of tertiary lymphoid structures and tumor-infiltrating lymphocytes in cholangiocarcinoma. J Immunother Cancer. 2025;13:e010173.","journal-title":"J Immunother Cancer"},{"key":"8750_CR56","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1093\/oncolo\/oyaf390","volume":"30","author":"X Lin","year":"2025","unstructured":"Lin X, Peng H, Liu K, Chen W, Shao X, Ning C, Li H, Yang D. Single-cell RNA sequencing analysis of intrahepatic cholangiocarcinoma reveals SPP1 facilitates disease progression via interaction with CD4\u2009+\u2009T cells. Oncol Lett. 2025;30:390.","journal-title":"Oncol Lett"},{"key":"8750_CR57","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1111\/jgh.16915","volume":"40","author":"C Liao","year":"2025","unstructured":"Liao C, Zhang Y, Yang J, Wang S, Li Z, Chen S, Xie Y, Xu L, Peng S, Zeng X. Single-Cell Transcriptomic Analysis Reveals an Aggressive Basal\u2010Like Tumor Cell Subpopulation Associated With Poor Prognosis in Intrahepatic Cholangiocarcinoma. J Gastroenterol Hepatol. 2025;40:1263\u201373.","journal-title":"J Gastroenterol Hepatol"},{"key":"8750_CR58","doi-asserted-by":"publisher","first-page":"31170","DOI":"10.1038\/s41598-025-17102-1","volume":"15","author":"X Gu","year":"2025","unstructured":"Gu X, Liu F, Zhang J, Nuermaimaiti N, Guo W, Dong X. Single-cell transcriptome sequencing reveals tumor stem cells and their molecular characteristics in intrahepatic cholangiocarcinoma. Sci Rep. 2025;15:31170.","journal-title":"Sci Rep"},{"key":"8750_CR59","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/s41420-024-02079-z","volume":"10","author":"B-Y Sun","year":"2024","unstructured":"Sun B-Y, Wang Z-T, Chen K-Z, Song Y, Wu J-F, Zhang D, Sun G-Q, Zhou J, Fan J, Hu B. Mobilization and activation of tumor-infiltrating dendritic cells inhibits lymph node metastasis in intrahepatic cholangiocarcinoma. Cell death discovery. 2024;10:304.","journal-title":"Cell death discovery"},{"key":"8750_CR60","doi-asserted-by":"crossref","first-page":"1666393","DOI":"10.3389\/fimmu.2025.1666393","volume":"16","author":"Y Song","year":"2025","unstructured":"Song Y, Huang S-w, Shu B, Zhou Y-X, Dai W-D, Sun B-Y. Gemcitabine-cisplatin chemotherapy plus anti-PD-L1 therapy reinvigorates antitumor immune response by reprogramming the intrahepatic cholangiocarcinoma microenvironment. Front Immunol. 2025;16:1666393.","journal-title":"Front Immunol"},{"key":"8750_CR61","doi-asserted-by":"crossref","first-page":"100226","DOI":"10.1016\/j.jhepr.2021.100226","volume":"3","author":"A Moeini","year":"2021","unstructured":"Moeini A, Haber PK, Sia D. Cell of origin in biliary tract cancers and clinical implications. JHEP Rep. 2021;3:100226.","journal-title":"JHEP Rep"},{"key":"8750_CR62","doi-asserted-by":"crossref","first-page":"3914","DOI":"10.1172\/JCI63065","volume":"122","author":"S Sekiya","year":"2012","unstructured":"Sekiya S, Suzuki A. Intrahepatic cholangiocarcinoma can arise from Notch-mediated conversion of hepatocytes. J Clin Investig. 2012;122:3914\u20138.","journal-title":"J Clin Investig"},{"key":"8750_CR63","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.ccell.2025.05.017","volume":"43","author":"F Huang","year":"2025","unstructured":"Huang F, Liu Z, Song Y, Wang G, Shi A, Chen T, Huang S, Lian S, Li K, Tang Y. Bile acids activate cancer-associated fibroblasts and induce an immunosuppressive microenvironment in cholangiocarcinoma. Cancer Cell. 2025;43:1460\u201375. e1410.","journal-title":"Cancer Cell"},{"key":"8750_CR64","first-page":"101949","volume":"41","author":"C Desterke","year":"2025","unstructured":"Desterke C, Franc\u00e9s R, Monge C, Fu Y, Marchio A, Pineau P, Mata-Garrido J. Single-cell RNAseq reveals adverse metabolic transcriptional program in intrahepatic cholangiocarcinoma malignant cells. Biochem Biophys Rep. 2025;41:101949.","journal-title":"Biochem Biophys Rep"},{"key":"8750_CR65","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.ccell.2021.03.012","volume":"39","author":"S Affo","year":"2021","unstructured":"Affo S, Nair A, Brundu F, Ravichandra A, Bhattacharjee S, Matsuda M, Chin L, Filliol A, Wen W, Song X. Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations. Cancer Cell. 2021;39:866\u201382. e811.","journal-title":"Cancer Cell"},{"key":"8750_CR66","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.1002\/cam4.1704","volume":"7","author":"M Sha","year":"2018","unstructured":"Sha M, Jeong S, Qiu Bj, Tong Y, Xia L, Xu N, Zhang J, Xia Q. Isolation of cancer-associated fibroblasts and its promotion to the progression of intrahepatic cholangiocarcinoma. Cancer Med. 2018;7:4665\u201377.","journal-title":"Cancer Med"},{"key":"8750_CR67","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.3390\/cancers13092134","volume":"13","author":"S Thongchot","year":"2021","unstructured":"Thongchot S, Vidoni C, Ferraresi A, Loilome W, Khuntikeo N, Sangkhamanon S, Titapun A, Isidoro C, Namwat N. Cancer-associated fibroblast-derived IL-6 determines unfavorable prognosis in cholangiocarcinoma by affecting autophagy-associated chemoresponse. Cancers. 2021;13:2134.","journal-title":"Cancers"},{"key":"8750_CR68","doi-asserted-by":"crossref","first-page":"897368","DOI":"10.3389\/fphar.2022.897368","volume":"13","author":"Y Kittirat","year":"2022","unstructured":"Kittirat Y, Suksawat M, Thongchot S, Padthaisong S, Phetcharaburanin J, Wangwiwatsin A, Klanrit P, Sangkhamanon S, Titapun A, Loilome W. Interleukin-6-derived cancer-associated fibroblasts activate STAT3 pathway contributing to gemcitabine resistance in cholangiocarcinoma. Front Pharmacol. 2022;13:897368.","journal-title":"Front Pharmacol"},{"key":"8750_CR69","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1476-4598-9-13","volume":"9","author":"K Utispan","year":"2010","unstructured":"Utispan K, Thuwajit P, Abiko Y, Charngkaew K, Paupairoj A, Chau-in S, Thuwajit C. Gene expression profiling of cholangiocarcinoma-derived fibroblast reveals alterations related to tumor progression and indicates periostin as a poor prognostic marker. Mol Cancer. 2010;9:13.","journal-title":"Mol Cancer"},{"key":"8750_CR70","first-page":"1147","volume":"43","author":"J Sonongbua","year":"2020","unstructured":"Sonongbua J, Siritungyong S, Thongchot S, Kamolhan T, Utispan K, Thuwajit P, Pongpaibul A, Wongkham S, Thuwajit C. Periostin induces epithelial-to-mesenchymal transition via the integrin \u03b15\u03b21\/TWIST-2 axis in cholangiocarcinoma. Oncol Rep. 2020;43:1147\u201358.","journal-title":"Oncol Rep"},{"key":"8750_CR71","doi-asserted-by":"crossref","unstructured":"Huang T-c, Feng W-d, Fang G-x, Zhang Q-h, Wei G-y, Li C-z, Wang J-m, Liu J-F. Cancer-associated fibroblasts regulate the development of cholangiocarcinoma through IL-6\/STAT3\/AKR1C3 signaling axis. Sci Rep. 2026.","DOI":"10.1038\/s41598-026-37583-y"},{"key":"8750_CR72","doi-asserted-by":"crossref","first-page":"960","DOI":"10.3390\/cells8090960","volume":"8","author":"P Papoutsoglou","year":"2019","unstructured":"Papoutsoglou P, Louis C, Coulouarn C. Transforming growth factor-beta (TGF\u03b2) signaling pathway in cholangiocarcinoma. Cells. 2019;8:960.","journal-title":"Cells"},{"key":"8750_CR73","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13046-014-0103-8","volume":"33","author":"S Zhao","year":"2014","unstructured":"Zhao S, Wang J, Qin C. Blockade of CXCL12\/CXCR4 signaling inhibits intrahepatic cholangiocarcinoma progression and metastasis via inactivation of canonical Wnt pathway. J Experimental Clin Cancer Res. 2014;33:103.","journal-title":"J Experimental Clin Cancer Res"},{"key":"8750_CR74","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1111\/cas.14151","volume":"110","author":"T Miyata","year":"2019","unstructured":"Miyata T, Yamashita YI, Yoshizumi T, Shiraishi M, Ohta M, Eguchi S, Aishima S, Fujioka H, Baba H. CXCL 12 expression in intrahepatic cholangiocarcinoma is associated with metastasis and poor prognosis. Cancer Sci. 2019;110:3197\u2013203.","journal-title":"Cancer Sci"},{"key":"8750_CR75","doi-asserted-by":"crossref","first-page":"101514","DOI":"10.1016\/j.tranon.2022.101514","volume":"25","author":"R Carloni","year":"2022","unstructured":"Carloni R, Rizzo A, Ricci AD, Di Federico A, De Luca R, Guven DC, Yalcin S, Brandi G. Targeting tumor microenvironment for cholangiocarcinoma: Opportunities for precision medicine. Translational Oncol. 2022;25:101514.","journal-title":"Translational Oncol"},{"key":"8750_CR76","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1080\/13543784.2021.1865308","volume":"30","author":"J Wang","year":"2021","unstructured":"Wang J, Ilyas S. Targeting the tumor microenvironment in cholangiocarcinoma: implications for therapy. Expert Opin Investig Drugs. 2021;30:429\u201338.","journal-title":"Expert Opin Investig Drugs"},{"key":"8750_CR77","doi-asserted-by":"crossref","unstructured":"Zhou M, Wang C, Lu S, Xu Y, Li Z, Jiang H, Ma Y. Tumor-associated macrophages in cholangiocarcinoma: complex interplay and potential therapeutic target. EBioMedicine. 2021;67.","DOI":"10.1016\/j.ebiom.2021.103375"},{"key":"8750_CR78","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.cell.2021.01.010","volume":"184","author":"S Cheng","year":"2021","unstructured":"Cheng S, Li Z, Gao R, Xing B, Gao Y, Yang Y, Qin S, Zhang L, Ouyang H, Du P. A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells. Cell. 2021;184:792\u2013809. e723.","journal-title":"Cell"},{"key":"8750_CR79","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","volume":"21","author":"F Veglia","year":"2021","unstructured":"Veglia F, Sanseviero E, Gabrilovich DI. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat Rev Immunol. 2021;21:485\u201398.","journal-title":"Nat Rev Immunol"},{"key":"8750_CR80","doi-asserted-by":"crossref","first-page":"2635867","DOI":"10.1080\/21645515.2026.2635867","volume":"22","author":"Y Xu","year":"2026","unstructured":"Xu Y, Xu X, Xu Y, Duan J. Immunotherapy impact of macrophage glycosylation on cholangiocarcinoma and its prognostic and immune microenvironment significance. Hum Vaccines Immunotherapeutics. 2026;22:2635867.","journal-title":"Hum Vaccines Immunotherapeutics"},{"key":"8750_CR81","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41571-019-0175-7","volume":"16","author":"Y Togashi","year":"2019","unstructured":"Togashi Y, Shitara K, Nishikawa H. Regulatory T cells in cancer immunosuppression\u2014implications for anticancer therapy. Nat reviews Clin Oncol. 2019;16:356\u201371.","journal-title":"Nat reviews Clin Oncol"},{"key":"8750_CR82","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.coi.2019.04.014","volume":"58","author":"M Philip","year":"2019","unstructured":"Philip M, Schietinger A. Heterogeneity and fate choice: T cell exhaustion in cancer and chronic infections. Curr Opin Immunol. 2019;58:98\u2013103.","journal-title":"Curr Opin Immunol"},{"key":"8750_CR83","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ccell.2018.03.012","volume":"33","author":"DS Thommen","year":"2018","unstructured":"Thommen DS, Schumacher TN. T cell dysfunction in cancer. Cancer Cell. 2018;33:547\u201362.","journal-title":"Cancer Cell"},{"key":"8750_CR84","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jhep.2021.10.030","volume":"76","author":"G-Y Ding","year":"2022","unstructured":"Ding G-Y, Ma J-Q, Yun J-P, Chen X, Ling Y, Zhang S, Shi J-Y, Chang Y-Q, Ji Y, Wang X-Y. Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma. J Hepatol. 2022;76:608\u201318.","journal-title":"J Hepatol"},{"key":"8750_CR85","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41568-019-0144-6","volume":"19","author":"C Saut\u00e8s-Fridman","year":"2019","unstructured":"Saut\u00e8s-Fridman C, Petitprez F, Calderaro J, Fridman WH. Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer. 2019;19:307\u201325.","journal-title":"Nat Rev Cancer"},{"key":"8750_CR86","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41586-019-1922-8","volume":"577","author":"BA Helmink","year":"2020","unstructured":"Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, Yizhak K, Sade-Feldman M, Blando J, Han G. B cells and tertiary lymphoid structures promote immunotherapy response. Nature. 2020;577:549\u201355.","journal-title":"Nature"},{"key":"8750_CR87","doi-asserted-by":"crossref","unstructured":"Wang H, Qian Y-W, Zhao Y, Sheng X, Xia C-Y, Chen H-Z, Cong W-M, He M-X, Dong H. A Grading system of intratumoral tertiary lymphoid structure for combined hepatocellular-cholangiocarcinoma: a multicenter pathological study. J Hepatocell Carcinoma. 2025:3011\u201327.","DOI":"10.2147\/JHC.S568933"},{"key":"8750_CR88","first-page":"1","volume":"3","author":"K Mody","year":"2019","unstructured":"Mody K, Kasi PM, Yang J, Surapaneni PK, Bekaii-Saab T, Ahn DH, Mahipal A, Sonbol MB, Starr JS, Roberts A. Circulating tumor DNA profiling of advanced biliary tract cancers. JCO precision Oncol. 2019;3:1\u20139.","journal-title":"JCO precision Oncol"},{"key":"8750_CR89","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.annonc.2022.10.506","volume":"34","author":"A Vogel","year":"2023","unstructured":"Vogel A, Bridgewater J, Edeline J, Kelley R, Kl\u00fcmpen H-J, Malka D, Primrose J, Rimassa L, Stenzinger A, Valle JW. Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:127\u201340.","journal-title":"Ann Oncol"},{"key":"8750_CR90","doi-asserted-by":"crossref","first-page":"1697056","DOI":"10.3389\/fimmu.2025.1697056","volume":"16","author":"J Xue","year":"2025","unstructured":"Xue J, Zhang L, Zhang K, Wu Y, Zhou K, Lu X. Metabolic collusion driving immune evasion in cholangiocarcinoma: unmasking the dual control of the immuno-metabolic microenvironment. Front Immunol. 2025;16:1697056.","journal-title":"Front Immunol"},{"key":"8750_CR91","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1136\/gutjnl-2025-335291","volume":"75","author":"F Liu","year":"2026","unstructured":"Liu F, Chen W, Zhang Z, Zeng W, Hu H, Ning S, Liao Z, Liu Y, Zhang H, Fu Q. Targeting Aurora kinase B regulates cholesterol metabolism and enhances chemoimmunotherapy in cholangiocarcinoma. Gut. 2026;75:353\u201366.","journal-title":"Gut"},{"key":"8750_CR92","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1136\/gutjnl-2024-333255","volume":"75","author":"M Mercado-G\u00f3mez","year":"2026","unstructured":"Mercado-G\u00f3mez M, Goikoetxea-Usandizaga N, Gin\u00e9 AE, Merlos Rodrigo MA, Afonso MB, Azkargorta M, Zapata-Pavas LE, Rejano-Gordillo CM, Romero MR, Mendizabal I. Role of CNNM4 in the progression of cholangiocarcinoma: implications for ferroptosis and therapeutic potential. Gut. 2026;75:341\u201352.","journal-title":"Gut"},{"key":"8750_CR93","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jhep.2018.12.004","volume":"70","author":"M Cadamuro","year":"2019","unstructured":"Cadamuro M, Brivio S, Mertens J, Vismara M, Moncsek A, Milani C, Fingas C, Malerba MC, Nardo G, Dall\u2019Olmo L. Platelet-derived growth factor-D enables liver myofibroblasts to promote tumor lymphangiogenesis in cholangiocarcinoma. J Hepatol. 2019;70:700\u20139.","journal-title":"J Hepatol"},{"key":"8750_CR94","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/ajg.2009.674","volume":"105","author":"A Thelen","year":"2010","unstructured":"Thelen A, Scholz A, Weichert W, Wiedenmann B, Neuhaus P, Ge\u00dfner R, Benckert C, Jonas S. Tumor-associated angiogenesis and lymphangiogenesis correlate with progression of intrahepatic cholangiocarcinoma. Official J Am Coll Gastroenterology| ACG. 2010;105:1123\u201332.","journal-title":"Official J Am Coll Gastroenterology| ACG"},{"key":"8750_CR95","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","volume":"9","author":"D-Y Oh","year":"2024","unstructured":"Oh D-Y, He AR, Bouattour M, Okusaka T, Qin S, Chen L-T, Kitano M, Lee C-k, Kim JW, Chen M-H. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study. lancet Gastroenterol Hepatol. 2024;9:694\u2013704.","journal-title":"lancet Gastroenterol Hepatol"},{"key":"8750_CR96","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, Yau T, Kl\u00fcmpen H-J, Chan SL, Ozaka M. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401:1853\u201365.","journal-title":"Lancet"},{"key":"8750_CR97","doi-asserted-by":"crossref","unstructured":"Zhixing L, Liu S, Yu H, Yuxi L, Li K, Li S, Mengchen S, Xiangyang W, Hu Y, Zhao C. Low-dose chemotherapy remodels hepatic immune landscape and potentiates anti-tumor response to immune checkpoint blockade in cholangiocarcinoma. Hepatology. 2026:101097.","DOI":"10.1097\/HEP.0000000000001735"},{"key":"8750_CR98","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1200\/JCO.24.00337","volume":"43","author":"T Macarulla","year":"2025","unstructured":"Macarulla T, Ren Z, Chon HJ, Park JO, Kim JW, Pressiani T, Li D, Zhukova L, Zhu AX, Chen M-H. Atezolizumab plus chemotherapy with or without bevacizumab in advanced biliary tract cancer: clinical and biomarker data from the randomized phase II IMbrave151 trial. J Clin Oncol. 2025;43:545\u201357.","journal-title":"J Clin Oncol"},{"key":"8750_CR99","first-page":"175628482311606","volume":"16","author":"K Wang","year":"2023","unstructured":"Wang K, Liu Z-H, Yu H-M, Cheng Y-Q, Xiang Y-J, Zhong J-Y, Ni Q-Z, Zhou L-P, Liang C, Zhou H-K. Efficacy and safety of a triple combination of atezolizumab, bevacizumab plus GEMOX for advanced biliary tract cancer: a multicenter, single-arm, retrospective study. Therapeutic Adv Gastroenterol. 2023;16:17562848231160630.","journal-title":"Therapeutic Adv Gastroenterol"},{"key":"8750_CR100","doi-asserted-by":"crossref","unstructured":"Huang F, Liu Z, Song Y, Wang G, Shi A, Chen T, Huang S, Lian S, Li K, Tang Y. Bile acids activate cancer-associated fibroblasts and induce an immunosuppressive microenvironment in cholangiocarcinoma. Cancer Cell. 2025.","DOI":"10.1016\/j.ccell.2025.05.017"},{"key":"8750_CR101","doi-asserted-by":"crossref","unstructured":"Cao Q-H, Li H, Sun P-F, Lu D-H, Tian B-W, Jiao K-F, Tian J-C, Wang Y-X, Jia J-S, Zhang Z-H. Pathomics-integrated multimodal model evaluate chemoimmunotherapy efficacy in unresectable intrahepatic cholangiocarcinoma. JHEP Rep. 2025:101557.","DOI":"10.1016\/j.jhepr.2025.101557"},{"key":"8750_CR102","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1038\/s41596-020-0292-x","volume":"15","author":"M Efremova","year":"2020","unstructured":"Efremova M, Vento-Tormo M, Teichmann SA, Vento-Tormo R. CellPhoneDB: inferring cell\u2013cell communication from combined expression of multi-subunit ligand\u2013receptor complexes. Nat Protoc. 2020;15:1484\u2013506.","journal-title":"Nat Protoc"},{"key":"8750_CR103","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1038\/s41467-021-21246-9","volume":"12","author":"S Jin","year":"2021","unstructured":"Jin S, Guerrero-Juarez CF, Zhang L, Chang I, Ramos R, Kuan C-H, Myung P, Plikus MV, Nie Q. Inference and analysis of cell-cell communication using CellChat. Nat Commun. 2021;12:1088.","journal-title":"Nat Commun"},{"key":"8750_CR104","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41592-019-0667-5","volume":"17","author":"R Browaeys","year":"2020","unstructured":"Browaeys R, Saelens W, Saeys Y. NicheNet: modeling intercellular communication by linking ligands to target genes. Nat Methods. 2020;17:159\u201362.","journal-title":"Nat Methods"},{"key":"8750_CR105","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","volume":"362","author":"J Valle","year":"2010","unstructured":"Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362:1273\u201381.","journal-title":"N Engl J Med"},{"key":"8750_CR106","doi-asserted-by":"publisher","first-page":"23501","DOI":"10.1038\/s41598-025-08602-1","volume":"15","author":"B Sha","year":"2025","unstructured":"Sha B, Tong F, Shu Q, Wu M, Zhao L, Zhang Y. Single cell RNA sequencing to identify an Immunogenic cell death related prognostic signature in intrahepatic cholangiocarcinoma. Sci Rep. 2025;15:23501.","journal-title":"Sci Rep"},{"key":"8750_CR107","doi-asserted-by":"crossref","unstructured":"Zhang T, Dou D, Liu Q, Xu D, Wang T, Liu R, Lu D, Zhao X, Wang S, Zhang H. Single-cell and bulk transcriptomic analyses uncover immune subtypes associated with programmed cell death features in intrahepatic cholangiocarcinoma. Sci Rep. 2026.","DOI":"10.1038\/s41598-026-44332-8"},{"key":"8750_CR108","doi-asserted-by":"crossref","unstructured":"Stuart T, Butler A, Hoffman P, Hafemeister C, Papalexi E, Mauck WM, Hao Y, Stoeckius M, Smibert P, Satija R. Comprehensive integration of single-cell data. Cell. 2019;177:1888\u20131902.e1821.","DOI":"10.1016\/j.cell.2019.05.031"},{"key":"8750_CR109","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","volume":"184","author":"Y Hao","year":"2021","unstructured":"Hao Y, Hao S, Andersen-Nissen E, Mauck WM, Zheng S, Butler A, Lee MJ, Wilk AJ, Darby C, Zager M. Integrated analysis of multimodal single-cell data. Cell. 2021;184:3573\u201387. e3529.","journal-title":"Cell"},{"key":"8750_CR110","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1038\/nm.4438","volume":"23","author":"L Broutier","year":"2017","unstructured":"Broutier L, Mastrogiovanni G, Verstegen MM, Francies HE, Gavarr\u00f3 LM, Bradshaw CR, Allen GE, Arnes-Benito R, Sidorova O, Gaspersz MP. Human primary liver cancer\u2013derived organoid cultures for disease modeling and drug screening. Nat Med. 2017;23:1424\u201335.","journal-title":"Nat Med"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08750-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08750-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08750-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T23:05:15Z","timestamp":1791673515000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08750-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":110,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8750"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08750-6","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]},"assertion":[{"value":"7 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. This review does not report new studies involving human participants, human data, human tissue, or animals.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No AI-assisted tools were used in the preparation of this manuscript.","order":3,"name":"Ethics","label":"Use of AI-assisted tools","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1278"}}